PMID- 36644451
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230202
IS  - 1939-4551 (Print)
IS  - 1939-4551 (Electronic)
IS  - 1939-4551 (Linking)
VI  - 16
IP  - 2
DP  - 2023 Feb
TI  - Omalizumab may protect allergic patients against COVID-19: A systematic review.
PG  - 100741
LID - 10.1016/j.waojou.2023.100741 [doi]
LID - 100741
AB  - Omalizumab, which downregulates the immunoglobulin E (IgE) receptor site on 
      plasmacytoid dendritic cells and thereby increases interferon-alpha (INF-alpha) 
      production, may shorten the duration of viral infections by enhancing the 
      antiviral immunity. A systematic review was conducted to investigate whether 
      previous anti-IgE treatment with omalizumab could protect against SARS-CoV-2 
      disease ("COVID-19") (infection, disease duration, and severity), and whether 
      IFN-alpha upregulation could be involved. The research included articles published 
      from March 2020 to January 2022. An accurate search was performed on 
      bibliographic biomedical database (MEDLINE - Pubmed, SCOPUS, EMBASE, BIOMED 
      CENTRAL, Google scholar, COCHRANE LIBRARY, ClinicalTrial.gov) including cohorts, 
      case reports and reviews. Different methods were used, based on the study design, 
      to assess the quality of eligible studies. Several authors link omalizumab to a 
      possible protection against viruses, but they often refer to studies carried out 
      before the pandemic and with viruses other than SARS-CoV-2 (severe acute 
      respiratory syndrome coronavirus 2) (eg, rhinoviruses -RV). Few cases of COVID-19 
      patients treated with omalizumab have been recorded, and, in most of them, no 
      increased susceptibility to severe disease was observed. According to these data, 
      the current indication is to continue omalizumab therapy during the pandemic. 
      Moreover, although omalizumab may enhance the antiviral immune response even for 
      SARS-CoV-2, further studies are needed to confirm this hypothesis. It would be 
      helpful to establish a registry of omalizumab-treated (or in treatment) patients 
      who have developed COVID-19. Finally, randomized controlled trials could be able 
      to demonstrate the effect of omalizumab in protecting against severe SARS-CoV-2, 
      through IFN-alpha upregulation or other immunological pathways.
CI  - (c) 2023 The Authors.
FAU - Ghiglioni, Daniele Giovanni
AU  - Ghiglioni DG
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Pediatria 
      Pneumoinfettivologia, Milan, Italy.
FAU - Cozzi, Et Laura
AU  - Cozzi EL
AD  - University of Milan, Milan, Italy.
FAU - Castagnoli, Riccardo
AU  - Castagnoli R
AD  - Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San 
      Matteo, University of Pavia, Pavia, Italy.
FAU - Bruschi, Gaia
AU  - Bruschi G
AD  - University of Milan, Milan, Italy.
FAU - Maffeis, Laura
AU  - Maffeis L
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Pediatria 
      Immunoinfettivologia, Milan, Italy.
FAU - Marchisio, Paola Giovanna
AU  - Marchisio PG
AD  - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Pediatria 
      Pneumoinfettivologia, Milan, Italy.
AD  - Department of Pathophysiology and Transplantation, University of Milan, Milan, 
      Italy.
FAU - Marseglia, Gian Luigi
AU  - Marseglia GL
AD  - Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San 
      Matteo, University of Pavia, Pavia, Italy.
FAU - Licari, Amelia
AU  - Licari A
AD  - Pediatric Clinic, Department of Pediatrics, Fondazione IRCCS Policlinico San 
      Matteo, University of Pavia, Pavia, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230109
PL  - United States
TA  - World Allergy Organ J
JT  - The World Allergy Organization journal
JID - 101481283
PMC - PMC9826982
OTO - NOTNLM
OT  - COVID-19
OT  - IFN-Alpha
OT  - Interferon
OT  - Omalizumab
OT  - SARS-CoV-2
EDAT- 2023/01/17 06:00
MHDA- 2023/01/17 06:01
PMCR- 2023/01/09
CRDT- 2023/01/16 03:02
PHST- 2022/08/08 00:00 [received]
PHST- 2022/12/10 00:00 [revised]
PHST- 2022/12/30 00:00 [accepted]
PHST- 2023/01/17 06:00 [pubmed]
PHST- 2023/01/17 06:01 [medline]
PHST- 2023/01/16 03:02 [entrez]
PHST- 2023/01/09 00:00 [pmc-release]
AID - S1939-4551(23)00001-7 [pii]
AID - 100741 [pii]
AID - 10.1016/j.waojou.2023.100741 [doi]
PST - ppublish
SO  - World Allergy Organ J. 2023 Feb;16(2):100741. doi: 10.1016/j.waojou.2023.100741. 
      Epub 2023 Jan 9.